Market Intelligence, Clinical Progress, and High-Purity Reagents for Anti-Angiogenic Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VEGFR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VEGFR2 ECD-Fc Fusion (Ig1-7 Domains). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed by MS. Also available as Kinase Domain Mutant Protein for resistance profiling. | View VEGFR2 Products |
| Gene Delivery | VEGFR2/KDR Lentivirus Premade Particles (Promise-ORF). Full-length ORF for stable cell line construction. Titers >1E8 TU/ml. Cell-based assays preserve native conformation. | View VEGFR2 Products |
| Benchmark Ab | Anti-VEGFR2 (Ramucirumab Sequence). Recombinant human IgG1 positive control. Sequence Verified. | View VEGFR2 Products |
| Validator | VEGFR2 siRNA Set (3 unique targets). For knockdown verification and specificity controls. | View VEGFR2 Products |
| Related Target | VEGFR1/FLT1. Decoy receptor regulation and off-target screening for selective VEGFR2 programs. | View VEGFR1 Products |
| Related Target | VEGFR3/FLT4. Lymphangiogenesis pathway and compensatory resistance; essential for VEGFR subfamily counter-screening. | View VEGFR3 Products |
| Related Target | VEGFA (Ligand). Primary ligand for VEGFR2; essential for receptor binding and ligand displacement assays. | View VEGFA Products |
| Related Target | Tie2. Synergistic angiogenesis pathway target for bispecific development. | View Tie2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluations | Human/Mouse/Cynomolgus VEGFR2 ECD proteins available with >95% purity, Sequence Verified, Theoretical MW confirmed by MS. |
| Internalization Efficiency (ADC Development) | High-purity ECD-Fc with native Ig-domain folding preserves conformational epitopes for internalization assays. |
| Subfamily Counter Screening | VEGFR1/VEGFR2/VEGFR3 homolog panel proteins strictly verified by mass spec and SEC for selectivity assays. |
| Kinase Domain Resistance Mutations | Full-length Lentivirus for stable BaF3-KDR cell line construction; supports TKI resistance modeling. Mutant kinase domain proteins available for ATP-competition assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Ramucirumab biosimilar sequence) and validated siRNA included. |
Live VEGFR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The VEGFR2 inhibitor market is transitioning from first-generation multi-kinase inhibitors toward next-generation precision biologics. While small-molecule TKIs (e.g., Apatinib, Lenvatinib) remain the backbone, the clinical success of Ramucirumab validated direct extracellular VEGFR2 blockade for gastric and lung cancers. The current pipeline emphasizes bispecific antibodies (VEGF/Tie2, VEGF/PD-L1), antibody-drug conjugates (ADCs), and subcutaneous formulations combined with immune checkpoint modulation. As resistance to TKIs emerges via kinase domain mutations, combination approaches with immunotherapy are becoming the dominant clinical trial design, aiming to overcome tumor microenvironment immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| mAb / Biosimilar | Eli Lilly (Ramucirumab), Samsung Bioepis | Gastric Cancer, NSCLC, Colorectal | Cynomolgus cross-reactivity essential for toxicology; ADCC reporter assays require high-purity ECD-Fc. |
| TKI (Selective / Multi-target) | Hengrui (Apatinib), Eisai (Lenvatinib), Bayer (Regorafenib) | HCC, Thyroid, RCC, Refractory Gastric | Kinase domain mutant proteins for resistance profiling; selectivity vs VEGFR1/PDGFR. |
| ADC (Investigational) | Emerging biotechs | Refractory Solid Tumors | Internalization rate quantification requires full-length stable cell lines via Lentivirus; payload cleavage validation. |
| Bispecific / Biologic | Preclinical/Phase I innovators | Solid Tumors (Immunotherapy combos) | Epitope mapping and dual-target binding validation using human/cyno ortholog protein panels. |
Molecular Differentiation & Assay Strategy Considerations
- Affinity Optimization: Not all high-affinity mAbs are ideal. Excessively high affinity (<10 pM) can cause binding site barrier effects. Recommended Kd range: 100 pM – 1 nM with moderate dissociation rate. Use SPR/BLI with our ECD-Fc for pH 6.0-7.4 profiling.
- Internalization: Essential for ADC development. VEGFR2 internalization efficiency varies by epitope (Ig-like Domain 2-3 vs 5-7). Use TarMart Lentivirus stable cell lines with pH-sensitive dye for quantitative analysis.
- Cross-species & Safety: Ramucirumab requires cyno binding; new mAbs must validate cyno cross-reactivity. Avoid VEGFR1 (FLT1) off-target binding to reduce hypertension/proteinuria. Use our VEGFR1/VEGFR2/VEGFR3 homolog panel.
- Kinase Domain Resistance: For TKI projects, build BaF3-KDR stable cell lines using our full-length Lentivirus to model resistance mutations.